Publicaciones en colaboración con investigadores/as de Hospital Virgen de la Arrixaca (22)

2023

  1. Circulating ST2, from biomarker to pathogenic mediator

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 672-674

2022

  1. Critical warm ischemia time point for cardiac donation after circulatory death

    American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328

2020

  1. Differences in the Interleukin-1β/Soluble ST2 Interplay Between Acute and Chronic Heart Failure

    Journal of Cardiovascular Translational Research

2019

  1. Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction

    Diabetes and Metabolism

  2. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction

    Journal of Molecular and Cellular Cardiology, Vol. 130, pp. 216-233

2018

  1. Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction

    Translational Research, Vol. 199, pp. 4-23

  2. Pulmonary Production of Soluble ST2 in Heart Failure

    Circulation. Heart failure, Vol. 11, Núm. 12, pp. e005488

2017

  1. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes

    PLoS ONE, Vol. 12, Núm. 2

  2. Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction

    Journal of Cardiovascular Translational Research, Vol. 10, Núm. 5-6, pp. 460-469

2016

  1. Clinical relevance of sST2 in cardiac diseases

    Clinical Chemistry and Laboratory Medicine, Vol. 54, Núm. 1, pp. 29-35

  2. Early oxidative damage induced by doxorubicin: Source of production, protection by GKT137831 and effect on Ca2+ transporters in HL-1 cardiomyocytes

    Archives of Biochemistry and Biophysics, Vol. 594, pp. 26-36

  3. Reformulated meat products protect against ischemia-induced cardiac damage

    Food and Function, Vol. 7, Núm. 2, pp. 992-1001

2015

  1. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction

    JACC: Heart Failure, Vol. 3, Núm. 1, pp. 50-58

2014

  1. Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes

    Free Radical Biology and Medicine, Vol. 67, pp. 19-29

  2. Galectin-3 expression in cardiac remodeling after myocardial infarction

    International Journal of Cardiology, Vol. 172, Núm. 1

  3. Modulation of IL-33/ST2 system in postinfarction heart failure: Correlation with cardiac remodelling markers

    European Journal of Clinical Investigation, Vol. 44, Núm. 7, pp. 643-651

2013

  1. High sensitive cardiac troponin T in the management of uncertain chest pain

    International Journal of Cardiology, Vol. 168, Núm. 4, pp. 4422-4423

  2. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity

    Free Radical Biology and Medicine, Vol. 57, pp. 188-200

2011

  1. Anabolic status and functional impairment in men with mild chronic heart failure

    American Journal of Cardiology, Vol. 108, Núm. 6, pp. 862-866

  2. Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system

    Free Radical Biology and Medicine, Vol. 51, Núm. 10, pp. 1861-1871